Addiction Medicine
Dopamine D3 receptor antagonist blocks cocaine reward effects
Published in Drug Week, August 25th, 2006
According to recent research published in the journal Neuropsychopharmacology, "Accumulating evidence indicates that dopamine (DA) D3 receptor antagonists appear highly promising in attenuating cocaine reward and relapse in preclinical models of addiction. In the present study, we investigated the effects of the novel D3 -selective antagonist NGB 2904 (N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide) on cocaine self-administration, cocaine-enhanced brain...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-08-25)
More Articles from Drug Week
- Allergy & Immunology
CC chemokine receptor antagonists selectively inhibit eosinophil influx into lungs - Cell Regulation
Helenalin plays important role in Akt signaling and Skp2 expression in 3T3-L1 preadipocytes - Cystic Fibrosis
Inspire initiates phase III trial of denufosol tetrasodium in cystic fibrosis patients - DNA Vaccine
Plasmid size up to 20 kbp does not limit lung gene transfer using DNA nanoparticles - Abdominal Infections
Study finds once-daily Avelox effective as multidose antibiotic in treating abdominal infections - Acid Reflux
Nexium maintains healing of erosive esophagitis better than lansoprazole, study shows - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
